1. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.
2. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Инсульт. Журн. неврол. и психиат. Прил. 2003; 8: 4–9.
3. Панченко Е.П., Кропачева Е.С. Профилактика тромбоэмболий у больных мерцательной аритмией. Медицинское информационное агентство, 2007.
4. Скворцова В.И., Чазова И.Е., Стаховская Л.В. Вторичная профилактика инсульта. М.: ПАГРИ, 2002.
5. Aguilar M, Hart R. Antiplatelet Therapy for Preventing Stroke in Patients With Nonvalvular Atrial Fibrillation and No Previous History of Stroke or Transient Ischemic Attacks. Stroke 2006; 37: 274–75.
6. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J. Neurol Neurosurg Psychiatry 1999; 66: 255–61.
7. Andersen L, Vestergaard P, Deichgraeber P et al. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart 2008; 94: 1607–13.
8. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 98–106.
9. Bachman D. Discontinuing chronic aspirin therapy: another risk factor for stroke? Ann Neurol 2002; 51: 137–8.
10. Bejot Y, Caillier M, Ben Salem D et al. Ischemic stroke subtypes and associated risk factors: a French population based study. J Neurol Neurosurg Psychiat 2008; 79: 1344–8.
11. Bernstein P, Jacobson B, Connor M, Becker P. Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events. J Neurol Sci 2009; 277 (1–2): 80–2.
12. Berrouschot J, Schwetlick B, von Twickel G et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006; 113 (1): 31–5.
13. Campbell C, Smyth S, Montalescot G et al. Aspirin Dose for the Prevention of Cardiovascular Disease. A Systematic Review. JAMA 2007; 297: 2018–24.
14. CAPRIE Steering Committee. A randomised blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348: 1333–8.
15. Chan F. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238–44.
16. Collet J, Himbert D, Steg P. Myocardial infarction after aspirin cessation in withdrawal. International. J Cardiol 2000; 76: 257–8.
17. Coull A, Lovett J, Rothwell P. Oxford Vascular Study. Population based study of early risk of stroke after transient ischemic attack or minor stroke: implications for public education and organization of services. BMJ 2004; 328: 326–8.
18. De Schryver E, van Gijn J, Kappelle L et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005; 252 (11): 1316–21.
19. Diener H, Cunha L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Nerol Sci 1996; 143: 5–13.
20. Diener H, Bogousslavsky J, Brass L et al. on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–7.
21. ESPRIT Study Group; Halkes P, van Gijn J, Kappelle L et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006; 367 (9523): 1665–73.
22. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischemic stroke and transient ischemic attack 2008. Cerebrovasc Dis 2008; 25 (5): 457–507.
23. Felmeden D, Lip G. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens 2005; 19: 185–96.
24. Gent M, Easton Y, Hachinski V et al. The Canadian American Ticlopidine Study (CATS) in Tromboembolic stroke. Lancet 1989; 1 (8649): 1215–20.
25. Gorelick P. Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy. Stroke 2002; 33: 862–5.
26. Graham G. Secondary stroke prevention: from guidelines to clinical practice. J Natl Med Assoc. 2008; 100(10):1125–1137.
27. Hamann G, Weimar C, Glahn J et al. Adherence to secondary stroke prevention strategies-results from the German Stroke Data Bank. Cerebrovasc Dis 2003; 15 (4): 282–8.
28. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing coomittee. Cerebrovasc Dis 2008; 25: 457–507.
29. Harbisoa Y. Ticlopidin versus aspirin for the prevention of recurrent stroke. Stroke 1992; 23 (12): 1723–7.
30. Kirshner H. Differentiating ischemic stroke subtypes: Risk factors and secondary prevention. J Neurol Sci 2009 [Epub ahead of print].
31. Landi F, Cesari M, Onder G еt al. Antithrombotic drugs in secondary stroke prevention among a community dwelling older population. J Neurol Neurosurg Psychiatry. 2003; 74 (8): 1100–4.
32. Lip G, Kamath S, Hart R. ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders. BMJ 2002; 325; 1161–3.
33. Lovett J, Coull A, Rothwell P. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569–73.
34. Michelson A, Cattaneo M, Eikelboom J еt al. Aspirin Resistance: Position Paper of the Working Group on Aspirin Resistance, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2005; 3: 1–3.
35. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic Atrial Fibrillation: Incidence, Prevalence, and Prediction of Stroke Using the Congestive Heart Failure, Hypertension, Age Greater than 75, Diabetes Mellitus, and Prior Stroke or Transient Ischemic Attack (CHADS2) Risk Stratification Scheme. Am Heart J 2008; 156 (1): 57–64.
36. Sacco RL, Foulkes MA, Mohr J et al. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989; 20: 983–9.
37. Saposnik G, Goodman S, Leiter L et al. Applying the Evidence. Do Patients With Stroke, Coronary Artery Disease, or Both Achieve Similar Treatment Goals? Stroke 2009.
38. Saxena R, Koudstaal P. Anticoagulants for Preventing Stroke in Patients With Nonrheumatic Atrial Fibrillation and a History of Stroke or Transient Ischemic Attack. Stroke 2004; 35: 1782–3.
39. Schwammenthal Y, Tsabari R, Shenkman B. Aspirin Responsiveness in Acute Brain Ischaemia: Association with Stroke Severity and Clinical Outcome. Cerebrovasc Dis 2008; 25: 355–61.
40. Serebruany V, Malinin, Eisert R, Sane D. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004; 75 (1): 40–7.
41. Serebruany V, Steinhubl S, Berger P et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005; 95 (10): 1218–22.
42. Tatli M, Guzel A, Akyuz A, Batun S. Could Platelet Aggregation Ratio Be an Indicator for Differential Diagnosis of Transient Ischemic Attack and Cerebral Ischemic Stroke? Cerebrovascular Diseases 2006; 22: 372–7.
43. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292: 1867–74.
44. Vande Griend J., Saseen J. Combination antiplatelet agents for secondary prevention of ischemic stroke. Pharmacotherapy 2008; 28 (10):1233–42.
45. Vermeer SE, Hollander M, Van Dijk E et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126–9.
46. Wang T, Bhatt D, Fox K et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007; 28 (18): 2200–7.
47. Weimar C, Diener H, Alberts M et al. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 2009; 40 (2): 350–4.

П.Р.Камчатнов, А.В.Чугунов, Б.Б.Радыш,Н.А.Михайлова